Nanomedicine firm Nanobiotix, a spinoff from the University of Buffalo, raises $18.1m in its initial public offering.
Nanobiotix, a France-based nanomedicine spinoff from the University of Buffalo (UB), has raised €14.2m ($18.1m) in its initial public offering.
Trading under the ticker code “NANO” on the NYSE Euronext, the Paris-based firm is trading 8,053,880 existing shares and 2,361,607 new shares at an issue price set at €6 a share. Market capitalisation was around €62.4m on the day of listing.
The money raised will be used with investment raised in a strategic partnership deal completed in August with PharmaEngine,…
